NNVC Nanoviricides Inc

  1. Stocks
  2. Healthcare
  3. NYSEAMERICAN: NNVC

Price (delayed)

$1.28

Market cap

$32.67M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.41

Enterprise value

$29.88M

?
Relative Growth: Rel. Growth: 11
Relative Strength: Rel. Strength: 60
Relative Valuation: Rel. Valuation: N/A
Relative Profitability: Rel. Profitability: 7

NanoViricides, Inc., a nano-biopharmaceutical company, discovers, develops, and commercializes therapeutics for the treatment of viral infections. The company is developing anti-influenza drug candidates at pre-clinical and advanced pre-clinical stage, which ...

Highlights
The EPS has grown by 35% YoY and by 4.7% from the previous quarter
NNVC's net income is up by 13% YoY
NNVC's quick ratio has surged by 97% year-on-year but it is down by 22% since the previous quarter
The equity has grown by 16% year-on-year but it has declined by 5% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.nanoviricides.com
Peers: BCRX NVAX GILD BMY

Key stats

What are the main financial stats of NNVC

NNVC stock price

How has the Nanoviricides stock price performed over time
Intraday
1.59%
1 week
-11.11%
1 month
9.4%
1 year
-10.49%
YTD
13.27%
QTD
-1.54%

Financial performance

How have Nanoviricides's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$8.31M
Net income
-$8.22M
Gross margin
N/A
Net margin
N/A
NNVC's net income is up by 13% YoY
Nanoviricides's operating income has increased by 13% YoY

Price vs fundamentals

How does NNVC's price correlate with its fundamentals

Growth

What is Nanoviricides's growth rate over time

Valuation

What is Nanoviricides stock price valuation
P/E
N/A
P/B
3.19
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has grown by 35% YoY and by 4.7% from the previous quarter
The stock's price to book (P/B) is 88% more than its 5-year quarterly average of 1.7 and 18% more than its last 4 quarters average of 2.7
The equity has grown by 16% year-on-year but it has declined by 5% since the previous quarter

Efficiency

How efficient is Nanoviricides business performance
Nanoviricides's return on equity has increased by 11% YoY
NNVC's return on assets is up by 10% year-on-year
Nanoviricides's return on invested capital has increased by 9% YoY

Dividends

What is NNVC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for NNVC.

Financial health

How did Nanoviricides financials performed over time
The current ratio has soared by 108% YoY but it has decreased by 16% QoQ
NNVC's quick ratio has surged by 97% year-on-year but it is down by 22% since the previous quarter
NNVC's debt is 100% lower than its equity
The equity has grown by 16% year-on-year but it has declined by 5% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.